Who
Harold E. Selick
Director
Company insider
Files Form 4 as: Director, Protagonist Therapeutics; Chief Executive Officer, Molecular Templates; Director, Pdl Biopharma; Director, Gyre Therapeutics.
In numbers
- Trades disclosed
- 115
- Buys
- 10
- Sells
- 1
- Bought
- $559K
- Sold
- $5.0M
- Companies
- 4
- Companies where not an officer
- 3
- First trade
- 14 Mar 2006
- Last trade
- 26 Mar 2026
- Last filed
- 27 Mar 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month. 1 lines have no legible date and are left out.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 26 Mar 2026filed 27 Mar 2026 | PTGX Protagonist TherapeuticsBiotechnology | SEC FORM 4 Code M | $309K24,000 at $12.88 | filing |
| 26 Mar 2026filed 27 Mar 2026 | PTGX Protagonist TherapeuticsBiotechnology | SEC FORM 4 Sold | $2.5M24,000 at $105.00 | filing |
| 26 Mar 2026filed 27 Mar 2026 | PTGX Protagonist Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —24,000 at $0.00 | filing |
| 26 Mar 2026filed 27 Mar 2026 | PTGX Protagonist Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —24,000 at $0.00 | filing |
| 26 Mar 2026filed 27 Mar 2026 | PTGX Protagonist TherapeuticsBiotechnology | SEC FORM 4 Code M | $309K24,000 at $12.88 | filing |
| 26 Mar 2026filed 27 Mar 2026 | PTGX Protagonist TherapeuticsBiotechnology | SEC FORM 4 Sold | $2.5M24,000 at $105.00 | filing |
| 9 Jan 2026filed 13 Jan 2026 | PTGX Protagonist TherapeuticsBiotechnology | SEC FORM 4 Code M | $60K14,299 at $4.21 | filing |
| 9 Jan 2026filed 13 Jan 2026 | PTGX Protagonist Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —14,299 at $0.00 | filing |
| 9 Jan 2026filed 13 Jan 2026 | PTGX Protagonist Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —14,299 at $0.00 | filing |
| 9 Jan 2026filed 13 Jan 2026 | PTGX Protagonist TherapeuticsBiotechnology | SEC FORM 4 Code M | $60K14,299 at $4.21 | filing |
| 2 Jan 2026filed 6 Jan 2026 | PTGX Protagonist TherapeuticsBiotechnology | SEC FORM 4 Code A | —2,695 at $0.00 | filing |
| 2 Jan 2026filed 6 Jan 2026 | PTGX Protagonist Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —3,762 at $0.00 | filing |
| 2 Jan 2026filed 6 Jan 2026 | PTGX Protagonist Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —3,762 at $0.00 | filing |
| 2 Jan 2026filed 6 Jan 2026 | PTGX Protagonist TherapeuticsBiotechnology | SEC FORM 4 Code A | —2,695 at $0.00 | filing |
| 28 Apr 2025filed 30 Apr 2025 | PTGX Protagonist Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —10,725 at $0.00 | filing |
| 28 Apr 2025filed 30 Apr 2025 | PTGX Protagonist TherapeuticsBiotechnology | SEC FORM 4 Code M | $12K10,725 at $1.16 | filing |
| 2 Jan 2025filed 6 Jan 2025 | PTGX Protagonist Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —6,584 at $0.00 | filing |
| 2 Jan 2025filed 6 Jan 2025 | PTGX Protagonist TherapeuticsBiotechnology | SEC FORM 4 Code A | —5,130 at $0.00 | filing |
| 27 Sep 2024filed 30 Sep 2024 | Molecular Templatesoption or derivative | SEC FORM 4 Code A | —1,000 at $0.00 | filing |
| 7 Mar 2024filed 11 Mar 2024 | PTGX Protagonist Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —6,490 at $0.00 | filing |
News
Protagonist Therapeutics (NASDAQ:PTGX) Downgraded by Wall Street Zen to BuyPTGX · dailypolitical.com · 11 Oct 2026
0 headlines in the last 90 days name Harold E. Selick; 1 article from the last 14 days about the 1 company they traded most, at most three about any one of them.